XML 41 R28.htm IDEA: XBRL DOCUMENT
v3.5.0.2

License and Collaboration Agreements - Additional Information (Detail) - USD ($) |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 30, 2016 | Mar. 01, 2016 | Sep. 16, 2014 | Apr. 30, 2016 | Mar. 31, 2016 | Nov. 30, 2015 | Aug. 31, 2015 | Mar. 31, 2015 | Jun. 30, 2014 | Jun. 30, 2013 | Feb. 29, 2012 | Jun. 30, 2016 | Dec. 31, 2013 | Dec. 31, 2010 | Dec. 31, 2009 | Jun. 30, 2016 | Dec. 31, 2013 | Dec. 31, 2007 | Jul. 31, 2016 | Dec. 31, 2015 | Jul. 31, 2015
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 147,000,000 |  |  |  |  |
Accounts receivable, net |  |  |  |  |  |  |  |  |  |  |  | $ 27,777,000 |  |  |  | 27,777,000 |  |  |  | $ 19,947,000 |
Liability for refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  | 12,500,000 |  |  |  | $ 0 |
ONZEALDTM (NKTR-102) [Member] | Turkey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca-ProStrakan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront payment, market access milestones, royalties and sales milestones |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of regulatory and commercial milestones | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to be received upon first commercial sales | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment to be received upon first commercial sale after final regulatory approval | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to be received upon first achievement of annual net sales target | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable, net |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  | 20,000,000 |  |  |  |  |
Liability for refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  | 12,500,000 |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | European Territory Except Turkey [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments receivable under license agreement | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable portion of upfront payment | $ 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from upfront payment |  |  |  |  |  |  |  |  |  |  |  | 3,300,000 |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 4,200,000 |  |  |  | 4,200,000 |  |  |  |  |
AstraZeneca AB [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liability to AZ for DTC advertising payments |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000
Reduction of revenue |  |  |  |  |  |  |  | (10,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | United States [Member] | Scenario, Forecast [Member] | Other Current Liabilities [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liability to AZ for DTC advertising payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |
AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,000,000 |  |  |  |  |  |
AstraZeneca AB [Member] | Movantik Fixed-dose Combination Program [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential contingent payments based on development events |  |  |  |  |  |  |  |  |  |  |  | 75,000,000 |  |  |  | 75,000,000 |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of post approval study costs to repay |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential reduction in royalties |  |  | $ 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential reduction in U.S. royalty rate for repayment |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  | $ 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | AstraZeneca-ProStrakan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  | 0 |  |  |  |  |
Received upfront and milestone payments |  |  |  | $ 28,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement |  | $ 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payment recognized as revenue |  |  |  |  | $ 28,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATETM (Hemophilia) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  | 0 |  |  |  |  |
Development milestones achieved |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATETM (Hemophilia) [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Roche [Member] | MIRCERA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received for product delivered in 2013 |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,600,000 |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  | $ 22,000,000 |  |  |  |  |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Roche [Member] | PEGASYS and MIRCERA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 3,800,000 |  |  |  | 3,800,000 |  |  |  |  |
Amgen, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 21,700,000 |  |  |  | 21,700,000 |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |
Bayer Healthcare LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 18,600,000 |  |  |  | 18,600,000 |  |  |  |  |
Payment made to Bayer for cost of Phase 3 clinical trial |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |  |  |  |
Bayer Healthcare LLC [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 |  |  |
Ophthotech Corporation [Member] | Fovista [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 17,500,000 |  |  |  | 17,500,000 |  |  |  |  |
Received upfront and milestone payments |  |  |  |  |  |  |  |  | $ 19,800,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential future development milestones upon acceptance for review of regulatory approval |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |  | 2,500,000 |  |  |  |  |
Other [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | $ 10,300,000 |  |  |  | $ 10,300,000 |  |  |  |  |

X
- Definition Consideration received for product delivered. + References No definition available. + Details
Name: | nktr_ConsiderationReceivedForProductDelivered
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent payment recognized as revenue. + References No definition available. + Details
Name: | nktr_ContingentPaymentRecognizedAsRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible milestone payments receivable upon achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | nktr_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase decrease in revenue. + References No definition available. + Details
Name: | nktr_IncreaseDecreaseInRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liability to AZ for DTC advertising payments. + References No definition available. + Details
Name: | nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability for refundable upfront payment. + References No definition available. + Details
Name: | nktr_LiabilityForRefundableUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment to be received upon first commercial sale after final regulatory approval. + References No definition available. + Details
Name: | nktr_MilestonePaymentToBeReceivedUponFirstCommercialSaleAfterFinalRegulatoryApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments to be received upon first achievement of annual net sales target. + References No definition available. + Details
Name: | nktr_MilestonePaymentsToBeReceivedUponFirstAchievementOfAnnualNetSalesTarget
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments to be received upon first commercial sales. + References No definition available. + Details
Name: | nktr_MilestonePaymentsToBeReceivedUponFirstCommercialSales
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable portion of upfront payment. + References No definition available. + Details
Name: | nktr_NonRefundablePortionOfUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment made to Bayer for cost of Phase 3 clinical trial. + References No definition available. + Details
Name: | nktr_PaymentForReimbursementOfCosts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of post approval study costs to repay. + References No definition available. + Details
Name: | nktr_PercentageOfPostApprovalStudyCostsToRepay
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on net sales. + References No definition available. + Details
Name: | nktr_PercentageOfRoyaltyOnNetSales
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontMilestonesRoyaltyAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment, market access milestones, royalties and sales milestones. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonesRoyaltiesAndSalesMilestones
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential contingent payments based on development events. + References No definition available. + Details
Name: | nktr_PotentialContingentPaymentsBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential development milestones upon acceptance for review of regulatory approval. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestonesUponAcceptanceForReviewOfRegulatoryApproval
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential reduction in future royalty payments to repay post approval studies. + References No definition available. + Details
Name: | nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential royalty reduction on sales to repay post-approval study if required. + References No definition available. + Details
Name: | nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized from upfront payment. + References No definition available. + Details
Name: | nktr_RevenueRecognizedFromUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments receivable under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivableUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront and milestone payments received by Our collaboration partner under sublicense arrangement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedByOurCollaborationPartnerUnderSublicenseArrangement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ONZEALDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_TR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithProStrakanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_DaiichiSankyoEuropeGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=nktr_EuropeanTerritoryExceptTurkeyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxaltaIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_PEGASYSAndMIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BayerHealthcareLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OphthotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_FovistaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |